Studies have found that the methylation status of some genes related to the EGFR signaling pathway changes in resistant cells, leading to sustained activation of the EGFR signaling pathway, causing tumor cells to develop resistance to TKI (173, 174) (Figure 4). This evidence concerns the gene EGFR and neoplasm.